-
Signature
-
/s/ Nathaniel S. Gardiner as attorney-in-fact
-
Stock symbol
-
ENTA
-
Transactions as of
-
Jan 11, 2022
-
Transactions value $
-
-$379,238
-
Form type
-
4
-
Date filed
-
1/13/2022, 06:54 PM
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
ENTA |
Common Stock |
Options Exercise |
$400K |
+9.2K |
+27.96% |
$43.46 |
42.1K |
Jan 11, 2022 |
Direct |
|
| transaction |
ENTA |
Common Stock |
Options Exercise |
$100K |
+3.34K |
+7.92% |
$30.00 |
45.4K |
Jan 11, 2022 |
Direct |
|
| transaction |
ENTA |
Common Stock |
Sale |
-$879K |
-12.5K |
-27.59% |
$70.13 |
32.9K |
Jan 11, 2022 |
Direct |
F1, F2 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
ENTA |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-9.2K |
-19.99% |
$0.00 |
36.8K |
Jan 11, 2022 |
Common Stock |
9.2K |
$43.46 |
Direct |
F3 |
| transaction |
ENTA |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-3.34K |
-9.53% |
$0.00 |
31.7K |
Jan 11, 2022 |
Common Stock |
3.34K |
$30.00 |
Direct |
F3 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
Remarks:
The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 above.